ASCO: Bayer’s Novel Drug Boosts Survival in Rare GI Cancer
CHICAGO (MedPage Today) — The novel kinase inhibitor regorafenib substantially reduces relapse risk from treatment-refractory gastrointestinal stromal tumors (GIST), clinical trial results showed.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com